Actively Recruiting / Ongoing Studies
Participate in Research
Interested in research? Check out the current Bronchiectasis and NTM studies listed below.
The MACrO2 study is for people with Mycobacterium avium complex (MAC) lung disease that has not responded to prescribed antibiotic medications. The study is researching a study medication, called epetraborole, designed to fight the bacteria that cause MAC lung disease. Participants may continue their prescribed antimicrobial medications. They will also receive either Epetrabarole or a placebo to take along with their existing antimicrobial medications. To learn more about this study, click here.
ARISE and ENCORE Studies for Newly Diagnosed MAC Patients
Researchers are currently conducting two (2) clinical trials to study a treatment and patient outcomes for newly diagnosed MAC lung disease patients:
The ENCORE study will assess a study drug as a potential treatment option for patients newly diagnosed with a MAC lung infection.
ARISE is a study looking to validate patient-reported outcomes instrument(s) for use in newly diagnosed MAC lung disease patients. Patient-reported outcomes instruments are important to accurately assess the impact of a disease and/or treatment on patients’ quality of life. ARISE is hoping to investigate which patient-reported outcomes instrument will be responsive and reliable for use among MAC patients.
To learn more about these studies and to see if you qualify, click here.
Mucus and mucus-related symptoms (sputum and phlegm production; chest congestion; cough) are some of the primary drivers leading to decreased quality of life in people with non-cystic fibrosis bronchiectasis (NCFBE). Renovion is conducting a clinical trial for people with NCFBE who are experiencing mucus symptoms as a significant component of their NCFBE diagnosis. The results of this study will enable a better understanding of the investigational product ARINA-1. ARINA-1 is a new mucolytic agent intended to decrease mucus viscosity and promote mucus clearance. The results of this study will aid in the development of the investigational product to improve quality of life in people with NCFBE. Renovion is collaborating with the COPD Foundation’s COPD360Net initiative to facilitate the success of this trial. To learn more about this study sponsored by Renovion, click here.
Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease (MAC2v3)
There are many different types of NTM, but mycobacterium avium complex (also known as ‘MAC’) is the most common. Treatment for MAC lung infections typically consists of a multi-drug (typically 3) antibiotic therapy for 18 to 24 months. When patients are on this treatment, they frequently experience debilitating side effects which can include nausea, diarrhea, fatigue, and in rare cases, more serious side effects such as hearing loss. Oregon Health and Science University is currently conducting a clinical trial to determine whether a third drug is necessary or whether taking two drugs can increase tolerability without a substantial loss of efficacy. To learn more about this study, click here.
Note to Researchers: The Bronchiectasis and NTM Research Registry is available to researchers conducting research studies and/or clinical trials. Researchers will go through an application process, which involves Advisory Committee approval for the use of the Registry. The Registry can be used for recruitment and/or data analysis. For more information on use of the Registry for research, please see the ‘For Healthcare Providers’ section on the Bronchiectasis and NTM Research Registry page.